Ani Pharmaceuticals (ANIP) Total Liabilities (2010 - 2026)

Ani Pharmaceuticals has disclosed Total Liabilities across 17 years of filings, most recently posting $896.9 million for Q2 2026.

• In Q2 2026, Total Liabilities rose 1.76% year-over-year to $896.9 million; the TTM figure through Jun 2026 stood at $896.9 million (up 1.76% YoY), while the FY2025 annual figure was $899.7 million, up 5.11% from the prior year.
• Total Liabilities came in at $896.9 million for Q2 2026 at Ani Pharmaceuticals, up from $859.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $902.3 million in Q3 2025 to a low of $398.8 million in Q1 2022.
• Average Total Liabilities over 5 years is $624.9 million, with a median of $443.5 million recorded in 2023.
• Year-over-year, Total Liabilities soared 100.25% in 2025 and rose 1.26% in 2026.
• Over 5 years, Total Liabilities stood at $421.5 million in 2022, then increased by 6.0% to $446.8 million in 2023, then surged by 91.56% to $855.9 million in 2024, then rose by 5.11% to $899.7 million in 2025, then decreased by 0.31% to $896.9 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $896.9 million in Q2 2026, $859.7 million in Q1 2026, and $899.7 million in Q4 2025.